Last updated: August 9, 2026
Diclofenac sodium topical solution 1.5% is a prescription nonsteroidal anti-inflammatory drug for osteoarthritis pain, primarily of the knee. Its commercial value depends less on the active ingredient, which is widely genericized, than on the delivery system. The formulation uses dimethyl sulfoxide, alcohol, propylene glycol, glycerin, phosphate buffer and water to improve diclofenac solubilization, skin penetration, spreading and dose delivery. The strongest opportunities are generic substitution, improved packaging, lower-irritation formulations, private-label distribution and differentiated topical delivery systems.
What is diclofenac sodium topical solution?
Diclofenac sodium topical solution is a small-molecule topical NSAID containing 1.5% diclofenac sodium by weight. The U.S. reference product is PENNSAID, approved by the FDA for the treatment of osteoarthritis pain of the knee. The product is applied directly to the affected knee and is distinct from diclofenac sodium topical gel products such as Voltaren Arthritis Pain.
| Attribute |
Diclofenac sodium topical solution 1.5% |
| Active ingredient |
Diclofenac sodium |
| Strength |
1.5% w/w |
| Dosage form |
Topical solution |
| Reference product |
PENNSAID |
| Original sponsor |
Nuvo Research |
| U.S. indication |
Osteoarthritis pain of the knee |
| Regulatory pathway |
NDA reference product; ANDA pathway available for equivalent generics |
| Drug class |
Nonsteroidal anti-inflammatory drug |
| Primary formulation challenge |
Delivering diclofenac through intact skin at a reproducible dose |
| Key excipient function |
Solubilization, penetration enhancement, wetting, evaporation control and skin feel |
The formulation is designed for local delivery while limiting the need for oral NSAID exposure. FDA labeling still includes class-wide NSAID warnings, including gastrointestinal, cardiovascular, renal and skin risks.[1]
What excipients are used in diclofenac sodium topical solution?
The principal excipients in the PENNSAID 1.5% formulation are dimethyl sulfoxide, alcohol, propylene glycol, glycerin, phosphate buffer and purified water.[1] Each component contributes to a multi-variable delivery system.
| Excipient or excipient class |
Formulation role |
Commercial or technical implication |
| Dimethyl sulfoxide |
Solvent and skin-penetration enhancer |
Supports delivery through the stratum corneum; can create odor and tolerability concerns |
| Alcohol |
Co-solvent and volatile spreading agent |
Improves drying and initial skin feel; may cause stinging or dryness |
| Propylene glycol |
Co-solvent, humectant and penetration aid |
Improves solubility and wetting; can produce irritation in sensitive users |
| Glycerin |
Humectant and skin-conditioning agent |
Reduces excessive dryness from alcohol and DMSO |
| Phosphate buffer |
pH control |
Supports chemical stability and diclofenac solubility |
| Purified water |
Vehicle |
Controls viscosity, dilution and overall application characteristics |
The system is not interchangeable on an excipient-by-excipient basis. Changing DMSO concentration, alcohol content, pH or solvent ratios can alter diclofenac flux, drying time, residue, irritation, viscosity and systemic exposure. These attributes can affect pharmaceutical equivalence, bioequivalence and regulatory acceptance.
How does dimethyl sulfoxide affect product performance?
DMSO is the central formulation differentiator. It penetrates the stratum corneum and can increase transport of diclofenac into underlying tissues. It also functions as a powerful solvent for polar and moderately lipophilic compounds.
The same properties create development constraints:
- Strong odor can reduce patient acceptance.
- Skin irritation can increase with concentration or repeated exposure.
- DMSO can alter transport of other substances applied to the skin.
- Packaging compatibility must be evaluated because DMSO can interact with polymers, elastomers, adhesives and closures.
- Residual odor and wetness can affect adherence to treatment.
A lower-DMSO formulation may offer a commercial advantage, but it cannot be treated as a simple reformulation. The sponsor must demonstrate that the new vehicle provides a comparable diclofenac delivery profile and does not materially increase systemic exposure.
What is the role of alcohol, propylene glycol and glycerin?
Alcohol improves wetting and evaporation. It can produce a fast-drying product, but excessive volatility can cause dose variability if the product is left open, dispensed inaccurately or exposed to heat.
Propylene glycol performs several functions at once. It increases solvent capacity, promotes skin wetting and may contribute to penetration enhancement. It can also cause contact irritation or sensitization in some users.
Glycerin moderates the drying effects of alcohol and DMSO. It improves skin feel and may reduce tightness after application. At higher concentrations, however, glycerin can make the product sticky and slow drying.
The commercial target is a balance between penetration, cosmetic acceptability and manufacturing robustness. A formulation with excellent in vitro delivery but poor odor or tack may underperform in the market.
What formulation patents protect diclofenac topical solution products?
Protection for diclofenac topical solution products can arise from several layers:
- Composition patents covering the solvent and penetration-enhancer system.
- Method-of-use patents covering treatment of osteoarthritis pain.
- Manufacturing patents covering mixing, pH adjustment, filtration or filling.
- Device or packaging patents covering metered-dose delivery.
- Regulatory exclusivity and patent listings associated with the reference NDA.
The original PENNSAID product relied on formulation technology developed around diclofenac delivery through the skin. Patent coverage for early formulation claims has generally reached or approached expiration in the United States, allowing generic competition through the ANDA pathway. Current status must be determined from the FDA Orange Book and relevant patent records for the specific reference-listed drug and strength.[2]
Does diclofenac sodium topical solution have Orange Book protection?
The FDA Orange Book identifies reference-listed drugs, approved abbreviated applications, patent information and applicable exclusivity. PENNSAID 1.5% is the relevant U.S. reference product for generic diclofenac sodium topical solution 1.5% products.[2]
The practical commercial position is:
- No biologic exclusivity applies because diclofenac sodium is a small molecule.
- Biosimilar litigation is irrelevant to this product.
- Generic applicants may use the ANDA route if they can satisfy sameness and bioequivalence requirements.
- Paragraph IV risk depends on any unexpired listed patents associated with the reference product.
- Formulation, device and method-of-use claims may create different barriers from the basic active-ingredient claims.
- A generic applicant must assess labeling carve-outs if protected use claims remain listed.
Because patent listings and litigation outcomes can change, an investment or launch decision should rely on the current Orange Book entry and Federal Register or court records rather than historical patent summaries.
When does diclofenac sodium topical solution lose exclusivity?
The active ingredient is long off patent. The relevant exclusivity question is product-specific rather than molecule-specific.
PENNSAID received FDA approval in 2009. Any original new chemical entity exclusivity has expired. Remaining market protection has depended on formulation patents, regulatory exclusivity, later-approved strengths and related product claims. Generic entry is therefore governed mainly by approval of ANDAs and the status of listed patents.
For commercial planning, the major milestones are:
| Milestone |
Commercial effect |
| 2009 PENNSAID 1.5% approval |
Established the prescription topical-solution market |
| Expiration of original regulatory exclusivity |
Opened the ANDA pathway, subject to patent status |
| Approval of generic 1.5% solutions |
Created direct price competition |
| Launch of OTC diclofenac gel |
Expanded consumer awareness of topical diclofenac but changed the competitive set |
| Ongoing patent and device review |
Determines remaining barriers for differentiated formulations |
Which companies are challenging diclofenac topical solution?
Generic competition is primarily expected from companies with established topical manufacturing, ANDA capabilities and commercial distribution. The competitive field includes generic pharmaceutical manufacturers, contract development and manufacturing organizations, specialty pharmaceutical companies and private-label distributors.
The commercial challenge is not limited to obtaining FDA approval. A successful entrant must also compete against:
- Generic diclofenac sodium topical solution.
- Prescription diclofenac gel.
- OTC Voltaren Arthritis Pain gel.
- Diclofenac sodium topical patches and creams in non-U.S. markets.
- Oral diclofenac and other topical NSAIDs.
- Physician preference for familiar branded delivery systems.
The generic product with the lowest acquisition cost may win pharmacy volume, while a differentiated product may capture non-commodity segments through improved usability or distribution.
What excipient improvements create commercial opportunities?
Lower-odor and lower-irritation vehicles
Reducing DMSO odor or replacing part of the solvent system could improve adherence. Candidate approaches include alternative penetration enhancers, optimized alcohol-to-polyol ratios, ester or ether cosolvents, and skin-compatible surfactant systems. Each change must be evaluated for diclofenac permeation, local tolerability and systemic exposure.
Metered-dose packaging
A metered pump can improve dose consistency relative to open dispensing. It can also reduce hand contamination, improve portability and support premium positioning. The device must be compatible with DMSO-containing formulations and maintain dose accuracy throughout container life.
Potential intellectual property may cover:
- Pump geometry.
- Dose volume.
- Container-closure materials.
- Priming and re-priming behavior.
- Tamper evidence.
- Orientation-independent dispensing.
Preservative-free packaging
A low-water or preservative-free solution may appeal to patients with sensitivity concerns. Unit-dose or airless packaging can reduce contamination risk. The business case depends on packaging cost, shelf life, manufacturing complexity and reimbursement.
Faster-drying formulations
A formulation with controlled evaporation could reduce transfer to clothing and shorten the interval before dressing. Excessively rapid drying, however, may reduce spreading and create dose loss. The development target is a short drying time with sufficient residence on the knee.
Reduced-transfer formulations
Film-forming polymers, controlled-viscosity vehicles and optimized humectant levels may reduce transfer after application. These systems must avoid tack, visible residue and altered diclofenac release.
Improved patient-use design
Commercial differentiation can come from the full administration system rather than the solution alone. Examples include an integrated applicator, dose counter, disposable wipe, application guide or packaging designed for one-handed use.
How does diclofenac topical solution compare with diclofenac gel?
| Product attribute |
Diclofenac sodium topical solution |
Diclofenac topical gel |
| Typical U.S. prescription strength |
1.5% solution |
Several strengths and formulations |
| OTC availability |
Generally prescription-led |
OTC 1% gel is widely marketed |
| Vehicle |
Solvent-based liquid |
Gelled semisolid |
| Drying |
Usually rapid because of volatile solvents |
Generally slower |
| Odor risk |
Higher if DMSO is used |
Usually lower, depending on formulation |
| Dose delivery |
Pump or measured drops |
Measured gel quantity |
| Main differentiation |
Penetration and low-viscosity spreading |
Consumer familiarity and broad retail access |
| Main commercial risk |
Irritation, odor and generic price erosion |
Strong OTC brand competition |
The solution has a technical advantage in spreading and drying. The gel has a commercial advantage in consumer familiarity and retail availability. A new solution would need a clear benefit in tolerability, convenience, dose accuracy or cost.
What regulatory pathway applies to new diclofenac topical solutions?
A generic equivalent can generally pursue an ANDA if it matches the reference product in active ingredient, dosage form, strength, route of administration and other applicable requirements. Topical products can present complex bioequivalence issues because local performance depends on formulation and skin delivery.
A materially different vehicle, indication, strength or delivery device may require a 505(b)(2) NDA rather than an ANDA. The 505(b)(2) route can support differentiated products but usually requires a stronger clinical, pharmacokinetic, dermatologic safety or comparative-performance package.
FDA evaluation may include:
- Drug release testing.
- In vitro permeation testing.
- Comparative physicochemical characterization.
- Local tolerability.
- Systemic pharmacokinetics.
- Dose delivery and container-closure performance.
- Stability under real-time and accelerated conditions.
The FDA’s product-specific guidance and topical-product bioequivalence framework are central to development planning.[3]
What manufacturing and IP barriers affect commercial entry?
Manufacturing is relatively accessible compared with biologics, but DMSO-containing products create specific controls. The manufacturer must establish:
- Uniform diclofenac distribution.
- Controlled pH.
- Consistent solvent ratios.
- Low particulate burden.
- Compatibility with filling equipment.
- Container-closure integrity.
- Accurate pump delivery.
- Stability after repeated opening.
- Worker exposure controls for volatile or penetrating solvents.
The most defensible IP position is likely to come from a combination of formulation and device claims. A basic substitution of one solvent for another may be commercially weak unless it delivers measurable advantages. Stronger claims could cover a defined solvent ratio, a specified permeation profile, a low-odor composition, a metered-dose package or a combination of vehicle and application method.
What generic launch risks exist for diclofenac sodium topical solution?
The principal risks are:
- Patent or regulatory delay tied to Orange Book listings.
- Failure to demonstrate topical bioequivalence.
- DMSO-related irritation or odor complaints.
- Packaging incompatibility and dose drift.
- Price compression after multiple generic launches.
- Limited reimbursement differentiation.
- Substitution by OTC diclofenac gel.
- Manufacturing deviations caused by solvent volatility or viscosity changes.
- Weak physician awareness outside the established PENNSAID market.
- Inadequate commercial scale for a low-volume prescription product.
A commodity generic strategy favors low-cost manufacturing and pharmacy access. A differentiated strategy favors a new device, improved tolerability, better cosmetic profile or a broader commercial channel.
What is the revenue opportunity for improved excipient systems?
The largest opportunity is not likely to come from the base generic molecule. It lies in capturing value from delivery-system improvements.
Potential commercial models include:
- ANDA launch with low-cost supply.
- Authorized generic or licensing arrangement.
- 505(b)(2) reformulation with premium pricing.
- Private-label prescription product.
- Co-development with a topical platform company.
- Regional licensing outside the United States.
- Contract manufacturing of DMSO-based topical solutions.
- Device-plus-drug product with branded differentiation.
Revenue exposure is concentrated in the U.S. prescription market, but geographic opportunities exist in countries where topical diclofenac is available by prescription or over the counter. Regulatory classification, local brand competition and national reimbursement rules differ materially. In many markets, diclofenac gel and topical patches are more established than the solution format.
How strong is the patent estate for diclofenac sodium topical solution?
The underlying diclofenac molecule has no meaningful remaining exclusivity. The estate is strongest when it covers a clinically relevant delivery advantage and a specific device or formulation architecture. It is weaker when claims broadly cover conventional solvents, ordinary pH adjustment or routine packaging.
For licensing or acquisition, the most valuable assets are likely to have:
- Evidence of improved skin delivery.
- Lower irritation or odor.
- Clear freedom-to-operate against PENNSAID-related claims.
- A defined regulatory pathway.
- Robust composition claims.
- Device claims that are difficult to design around.
- Data supporting stability and dose uniformity.
- Commercially practical excipients with global supply.
Key Takeaways
- Diclofenac sodium topical solution 1.5% is a solvent-driven topical NSAID product, not merely diclofenac dissolved in water.
- DMSO is the principal delivery-enabling excipient and the main source of odor, tolerability and packaging complexity.
- Propylene glycol, alcohol and glycerin jointly control solubility, penetration, evaporation and skin feel.
- U.S. exclusivity is primarily a formulation, device and patent-listing issue because diclofenac is long off patent.
- Biosimilar risk does not apply; generic and 505(b)(2) competition are the relevant pathways.
- The best commercial opportunities are lower-odor vehicles, lower-irritation systems, metered packaging, preservative-free delivery and improved dose accuracy.
- A commodity generic is exposed to rapid price erosion and competition from OTC diclofenac gel.
- A premium product requires measurable advantages supported by topical bioequivalence, tolerability, stability and device data.
FAQs
Can DMSO be removed from diclofenac sodium topical solution?
DMSO can be reduced or replaced in development, but the resulting product may no longer be equivalent to the reference formulation. The sponsor must demonstrate acceptable diclofenac delivery, local tolerability, systemic exposure and stability.
Is diclofenac sodium topical solution eligible for an ANDA?
A product that matches the reference-listed drug in the required pharmaceutical characteristics may pursue an ANDA. A materially different formulation or delivery system may require a 505(b)(2) NDA.
Can a new excipient create patent protection for diclofenac solution?
Yes. A novel excipient combination can support composition, use or formulation claims if the claims are new, non-obvious and adequately supported. Routine solvent substitution generally provides weaker protection.
Is a metered pump commercially superior to a dropper?
A metered pump can improve dose consistency, reduce hand contact and support brand differentiation. Its value depends on pump accuracy, compatibility with the solvent system, cost and patient acceptance.
Does topical diclofenac solution eliminate NSAID systemic safety concerns?
No. Topical delivery may reduce systemic exposure compared with oral administration, but FDA labeling retains NSAID-related warnings and contraindications.[1]
References
-
U.S. Food and Drug Administration. (2023). PENNSAID- diclofenac sodium solution prescribing information. Drugs@FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Product-specific guidance for generic drug development and topical dermatologic drug products. FDA.
-
U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.
-
U.S. Food and Drug Administration. (2022). Diclofenac topical products: Labeling and safety information. FDA.
